Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vidarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.97 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.97 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.97 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.97 |
| ▸ | DPP4 | P27487 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.97 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.97 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.97 |
| ▸ | GAPDH | P04406 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | STAT6 | P42226 | 1/20 | 0.97 |
| ▸ | PI4KA | P42356 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.97 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.97 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.97 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.97 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vidarabine SCHEMBL30994790 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL15741481 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL4993136 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL14719528 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL2929 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL5078118 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL5500833 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL4280020 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL10764695 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL27624165 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642247-B2 | 1,3,5-triazines for treatment of viral diseases | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2010-01-05 | — | — | US | claimed |
| WO-2007092432-A2 | LIQUID-FILLED NANODROPLETS FOR ANTI-CANCER THERAPY | IMARX THERAPEUTICS, INC. (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070184076-A1 | Liquid-filled nanodroplets for anti-cancer therapy | IMA RY THERAPEUTICS, INC. | 2007-08-09 | — | — | US | claimed |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-06-21 | — | — | US | claimed |
| US-20060034904-A1 | Transdermal delivery using emcapsulated agent activated by ultrasound and or heat | ULTRA-SONIC TECHNOLOGIES, L.L.C. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2004060447-A2 | TRANSDERMAL DELIVERY USING ENCAPSULATED AGENT ACTIVATED BY ULTRASOUND AND/OR HEAT | ULTRA-SONIC TECHNOLOGIES, L.L.C. (US) | 2004-07-22 | — | — | WO | claimed |
| US-20030198664-A1 | Lipid mediated screening of drug candidates for identification of active compounds | FLORIDA, UNIVERSITY OF | 2003-10-23 | — | — | US | claimed |
| WO-2003083443-A2 | LIPID MEDIATED SCREENING OF DRUG CANDIDATES FOR IDENTIFICATION OF ACTIVE COMPOUNDS | UNIVERSITY OF FLORIDA (US) | 2003-10-09 | — | — | WO | claimed |
| US-20030147812-A1 | Device and methods for initiating chemical reactions and for the targeted delivery of drugs or other agents | DORNIER MEDTECH SYSTEMS GMBH. (DE) | 2003-08-07 | — | — | US | claimed |
| EP-0740528-B1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX THERAPEUTICS INC (US) | 2003-03-26 | — | — | EP | claimed |
| EP-0983060-A4 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | claimed |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| EP-0983060-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| US-5770222-A | Therapeutic drug delivery systems | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-23 | — | — | US | claimed |
| EP-0740528-A4 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP (US) | 1998-04-01 | — | — | EP | claimed |
| US-5733572-A | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles | IMARX PHARMACEUTICAL CORP. (US) | 1998-03-31 | — | — | US | claimed |
| CN-1137748-A | Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor | IMARX PHARMACEUTICAL CORP (US) | 1996-12-11 | — | — | CN | claimed |
| EP-0740528-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1996-11-06 | — | — | EP | claimed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | HAVCR2, EIF2AK2, IKZF3 | ADORA3 2361/4885ADORA2A 2510/4885ADORA2B 3704/4885 |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | EXOSC9, EXOSC5, EXOSC4 | ADORA3 749/4885ADORA2A 320/4885ADORA2B 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.